checkAd
    Startseite > Aktien > UroGen Pharma > Nachrichten
    UroGen Pharma Aktie
    13,300
     
    EUR
    +2,31 %
    +0,300 EUR
    Letzter Kurs 02.05.24 Tradegate
    13,100
     
    EUR
    462 STK
    Geldkurs 11:05:47
    13,600
     
    EUR
    444 STK
    Briefkurs 11:05:47
    ISIN: IL0011407140 · WKN: A2DTCV · SYM: UR8 · Israel

    Neueste Nachrichten

    UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
    17.04.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
    15.04.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
    03.04.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
    14.03.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    08.03.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
    04.03.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
    26.02.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Pharma to Participate at Upcoming Investor Conferences
    01.02.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
    24.01.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
    17.01.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Pharma to Participate in the B. Riley Healthcare Conference
    11.01.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    08.12.23 · Business Wire (engl.) · UroGen Pharma